Navigation Links
Merrimack Pharmaceuticals Announces that Recruitment is Open in a Phase 1 Combination Study of MM-111 with Multiple Treatment Regimens in HER2 Positive Patients
Date:4/20/2011

CAMBRIDGE, Mass., April 20, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that five patients have received therapy in a Phase I clinical study combining MM-111 with multiple standard treatment regimens for patients with advanced HER2 positive (HER2+) solid tumors.

(Logo: http://photos.prnewswire.com/prnh/20100913/NE63515LOGO)

MM-111 is a bi-specific antibody that targets tumor cells over-expressing ErbB2/HER2. MM-111 is designed to inhibit the signaling between ErbB2/HER2 and ErbB3/HER3 thus disabling downstream signaling, including the phosphatidylinositol 3-kinase (PI3K) pathway, and preventing tumor proliferation. In this study, Merrimack is evaluating whether MM-111 could be safely added to standard therapies used to treat HER2 positive cancers. The study could also provide preliminary evidence of activity in patients with advanced/metastatic HER2 positive disease, an area of high unmet medical need for which there are limited treatment options.

"HER2 positive cancers are historically more aggressive and carry a poorer prognosis than other types of solid tumors," says Clet Niyikiza, Ph.D., Executive Vice President of Development, Merrimack Pharmaceuticals. "Patients with HER2 positive metastatic cancer eventually progress or are intolerant of current approved regimens. Close to half of the patients treated with such regimens fail to respond."

The Phase 1 study will evaluate the human safety and pharmacokinetics of MM-111 when administered in combination with either 1) cisplatin, capecitabine, and trastuzumab; 2) lapatinib and trastuzumab; or 3) paclitaxel and trastuzumab in patients with HER2 positive solid tumors. The study is being run in collaboration with US Oncology, a leading integrated oncology company that is affiliated with more than 1,400 physicians nationwide.

"Because ErbB3 activation has been indicated as a cause of resistance to current HER2 targeted treatments and chemotherapies, we pl
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Merrimack Pharmaceuticals Announces the Addition of Michael Porter to its Board of Directors
2. Merrimack Pharmaceuticals to Present at the 2010 Stifel Nicolaus Healthcare Conference
3. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
4. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
5. Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013
6. Auxilium Pharmaceuticals to Present at the Deutsche Bank 36th Annual Health Care Conference
7. Sagent Pharmaceuticals Upsizes and Prices Initial Public Offering
8. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
9. Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection
10. Bexion Pharmaceuticals Receives Outstanding Biotech Innovation Award
11. Sigma-Tau Pharmaceuticals Announces Approval for New Manufacturing Process for ONCASPAR® (Pegaspargase) Primary Ingredient
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Astellas has appointed James Kellerman ... the Americas. Kellerman will report directly to Linda ... Astellas. In his new role, Kellerman will lead a ... and manage the region,s intellectual property matters, coordinating closely ... very pleased to welcome Jim to Astellas. Jim brings ...
(Date:9/2/2014)... Sept. 2, 2014  Numotion is pleased to announce the ... of Directors. Mark is a 30-year retired ... positions across the organization and was a GE Company Officer ... Mark spent many years running business units within GE Healthcare, ... Healthcare Americas. "We are delighted to welcome ...
(Date:9/2/2014)... , Sept. 2, 2014  On July 31, ... to Congress that it is moving forward to regulate ... the minutes until laboratories throughout the U.S. will need ... Although some medical laboratories may subscribe to the ... FDA to put guidelines in place, it,s widely acknowledged ...
Breaking Medicine Technology:Leading Intellectual Property Counsel, James Kellerman, Joins Astellas as Vice President 2FDA Tells Congress It Intends to Regulate LDTs! Web Conference to Provide Straight Talk on Essential Steps Clinical Laboratories and Pathology Groups Will Need to Take to Comply 2FDA Tells Congress It Intends to Regulate LDTs! Web Conference to Provide Straight Talk on Essential Steps Clinical Laboratories and Pathology Groups Will Need to Take to Comply 3
... Solutions Development Company (MSDC), a drug discovery and ... metabolic diseases, announced today that it has launched ... second drug candidate for the treatment of type ... placebo-controlled clinical trial will involve approximately 125 patients ...
... SAN and NYSE: SNY ) announced today ... Rights (CVRs) offered to Genzyme shareholders as part of ... by the U.S. Securities and Exchange Commission. ... Genzyme, sanofi-aventis has commenced an exchange offer to acquire ...
Cached Medicine Technology:Metabolic Solutions Development Company Launches Phase 2a Trial of Its Second Compound to Treat Type 2 Diabetes 2Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective 2Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective 3
(Date:9/2/2014)... Sept. 2, 2014 (HealthDay News) -- Two new studies ... suggests that 6-year-olds who were breast-fed have a lower ... bottle-fed infants, while the other finds a similar trend ... the "many benefits of breast-feeding in the immediate newborn ... Hill Hospital in New York City. She was not ...
(Date:9/2/2014)... Sept. 2, 2014 (HealthDay News) -- A leading group ... of the major form of advanced breast cancer. ... to drugs that target the HER2 protein, the American ... news release. Almost 80 percent of women ... noted. "In releasing this guideline, our aim is ...
(Date:9/2/2014)... Doctors trained in locations with less intensive (and expensive) ... clinical decisions that spare patients unnecessary and excessive medical ... Internal Medicine . , "Growing concern about the costs ... assessing physicians, ability to avoid the provision of unnecessary ... Outcomes Group and The Dartmouth Institute for Health ...
(Date:9/2/2014)... When weather conditions are right, tornadoes can occur ... a path of destruction. In fact, the United States leads ... tornadoes per year. Rainbow International offers the following safety tips ... , Select a safe place such as ... with no windows to stay during the storm. If a ...
(Date:9/2/2014)... 2014 Alliance Strategies Group, LLC, an ... marketing is pleased to announce it is bringing two ... Freedom as well as The Red Report ... one million concerned Americans who can be reached via ... are honored to continue providing our clients and advertisers ...
Breaking Medicine News(10 mins):Health News:More Evidence Breast-Feeding Lowers Child's Risk of Infections, Allergies 2Health News:New Guidelines for Treating Form of Advanced Breast Cancer 2Health News:Residency training predicts physicians' ability to practice conservatively 2Health News:Act Quickly in Case of Tornado: Rainbow International® Offers Tips on How to Be Prepared for a Tornado 2Health News:ASG Continues to Bring New Lists to Market 2Health News:ASG Continues to Bring New Lists to Market 3
... increasing as more and younger people dye their hair, warn ... face and, in severe cases, facial swelling may occur. ... para-phenylenediamine (PPD) and other related agents. During the 20th century, ... it was banned from hair dyes in Germany, France, and ...
... diphenyl trichloroethane is the best pesticide and also an established carcinogen. ... at a very high// level even after many years of its ... ,The high level of DDT in the sea is due ... into local sewers which eventually lead into the sea. This has ...
... An intervention to improve communication between clinicians in the ... dying patient significantly reduces feelings of stress,// anxiety, and ... that appears in the February 1, 2007 issue of ... ,The study, funded in part by the National Institute ...
... King County have been diagnosed with a strain of HIV ... concerned it could spread further.// ,At least two ... another type has limited effectiveness, officials from Public Health — ... there can be more infections, and the gay community is ...
... wheat variety have led to a major advance in breeding ... papers published in the journal Plant Physiology researchers describe the ... work by excluding salt from different parts of the plant: ... discovery of the two genes is the subject of international ...
... Although the overall cancer death rate in African Americans has ... 35 percent higher in African American men and 18// percent ... women in the most recent time period (2003). ... past 10 years because rates have decreased faster in African ...
Cached Medicine News:Health News:Communication in the ICU to Be Strengthened 2Health News:Communication in the ICU to Be Strengthened 3Health News:New HIV Threat Found in King County 2Health News:Ancient Genes Used to Produce Salt-Tolerant Wheat 2Health News:Cancer Death Rates High in African-Americans 2
... Basic ergonomic chairs with concave ... support • Select options like seats, ... • BTP/1Q-PAL chairs are recommended for ... clean room, static control, health care ...
... Basic ergonomic chairs with concave ... support • Select options like seats, ... • BTP/1Q-PAL chairs are recommended for ... clean room, static control, health care ...
... Basic ergonomic chairs with concave seats ... • Select options like seats, backrests, ... BTP/1Q-PAL chairs are recommended for the ... room, static control, health care and ...
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
Medicine Products: